Listen
RADIOGARDASE (Prussian blue), antidote to caesium and thallium
ANTIDOTE - New medicinal product
Opinions on drugs -
Posted on
Apr 12 2018
Reason for request
Inclusion
Substantial clinical benefit in the treatment of internal caesium or thallium contamination, but no clinical benefit demonstrated compared with current therapeutic management treatment
- RADIOGARDASE has a Marketing Authorisation in the treatmentof known or suspected internal caesium or thallium contamination, whether radioactive or not.
- It is a chelating agent that reduces the half-life of caesium and thallium in the body.
- Its Marketing Authorisation approves a well-established use of Prussian blue (PB) in the management of caesium or thallium contamination and is mainly based on bibliographic data.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
English version
Contact Us
Évaluation des médicaments
